Celltrion Healthcare launches'Truxima' in Brazil Direct marketing activities to expand the Latin American market -Provincial bidding wins in three regions of Brazil... Exclusive supply of'Truxima' in the region with successful debut -'Truxima launching symposium' held... Proving high interest in'Truxima' with participation of 500 KOL -Direct sales of'Truxima' in Brazil... [2020-05-27] Celltrion Healthcare launches'Truxima' (component name: rituximab), a biosimilar for treating blood cancer, in Brazil.?As a result, the company has sold all three biosimilars such as'Ramshima' (ingredient name: Infliximab),'Truxima', and'Herjuma' (ingredient name: Trastuzumab) in Brazil, the largest market in Latin America. Celltrion Healthcare Earlier this month, Brazil 3 state?one?has succeeded in surpassing its competitors in bid Thank bidding held in the rituximab.?The company plans to make a full-fledged expansion of the Brazilian market by exclusively selling'Truxima' in the public markets in these regions for the next year starting from June, after the supply contracts with the relevant governments have been completed. Celltrion HealthCare will launch the Truxima Launching Symposium for key Opinion Leader (KOL) medical personnel in the biopharmaceutical industry in Sao Paulo, Brazil on the 26th (local time) to coincide with the launch of'Truxima'. Held. The event was held online to prevent the spread of the Corona 19 (COVID-19) virus, and over 500 medical personnel participated in the event, showing a high interest in'Truxima'.?In particular, despite the fact that the symposium was targeted at KOL in Brazil, medical teams from nearby Latin American countries who learned about the event in advance also wanted to attend the symposium, and they also participated in the event, creating a place for greater information exchange.?As Celltrion Healthcare confirmed the interests and needs of Latin American medical staff about'Truxima' through the event, it plans to increase marketing activities centering on the hospitals where the participants belong. Einstein Hospital?2?President Dr. Claudio Lottenberg, who?participated as a presenter,?said, "Safety and efficacy have been proven enough as'Truxima' has been expanding its prescriptions in the United States, Europe, and around the world." "When Truxima, a competitive company, is launched in Brazil, we expect it will be very helpful in alleviating the medical financial burden of the Brazilian government and improving patient access to medical services." 'Truxima' is the only rituximab biosimilar released in Latin America and is approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).?Particularly, in Europe, it is a drug that has been proven to be more prescribed than original drugs, so it is expected to be active in the Latin American region, which is heavily influenced by the US and European drug markets. Celltrion Healthcare's Brazilian subsidiary has expanded its marketing and sales force for direct sales starting this year, and has already secured profitability by launching'Truxima' with thorough preparation and successful bids.?Celltrion Healthcare plans to expand its direct sales to other products by expanding the number of local corporations by the end of this year. An official from Celltrion Healthcare said, ?Brazil is a key country that accounts for half of the Latin American market. It is expected that the launch of'Truxima' will have a positive impact on neighboring countries such as Chile and Ecuador. In spite of the difficult conditions that are limited, we will do our best to achieve good results in the regions of Latin America where we are planning to bid in the future because we have been able to beat competitors with the competence of pure local corporations, win the Brazilian state bid and prove our direct competitiveness. "I said.